ACIP updates HPV vaccine recommendations for adults

  • Meites E & al.
  • MMWR Morb Mortal Wkly Rep
  • 16.08.2019

  • von Liz Scherer
  • Clinical Essentials
Der Zugang zum gesamten Inhalt dieser Seite ist nur Angehörigen medizinischer Fachkreise vorbehalten. Der Zugang zum gesamten Inhalt dieser Seite ist nur Angehörigen medizinischer Fachkreise vorbehalten.

Takeaway

  • Advisory Committee on Immunization Practices (ACIP, 2019) updated HPV vaccine recommendations, highlighting the need for shared clinical decision-making in adults ≥26 years.

Why this matters

  • HPV vaccine effectiveness (VE) may be low among adults with multiple lifetime sex partners and/or previous infections with vaccine-type HPV.
  • Discuss sexual history to determine potential benefit of HPV vaccination; consider HPV vaccine in adults aged 27-45 years with new sexual partners, no indication of prior exposure as both are HPV risk factors.

Key points

  • Routine HPV vaccination recommendations in children, adolescents, young adults aged 9-26 years remain unchanged.
  • Recommendations in pregnant women have not changed.
  • HPV vaccination is not recommended for adults >45 years.
  • Testing is unavailable to determine immunity status, continued susceptibility to vaccine-type HPV.
  • Most adults have been exposed to some HPV types, although not those targeted by vaccination.